Naringenin Nanoformulations for Neurodegenerative Diseases

Curr Pharm Biotechnol. 2024 Feb 12. doi: 10.2174/0113892010281459240118091137. Online ahead of print.ABSTRACTGlioblastoma (GBM) is a grade-IV astrocytoma, which is the most common and aggressive type of brain tumor, spreads rapidly and has a life-threatening catastrophic effect. GBM mostly occurs in adults with an average survival time of 15 to 18 months, and the overall mortality rate is 5%. Significant invasion and drug resistance activity cause the poor diagnosis of GBM. Naringenin (NRG) is a plant secondary metabolite byproduct of the flavanone subgroup. NRG can cross the blood-brain barrier and deliver drugs into the central nervous system when conjugated with appropriate nanocarriers and can overcome the challenges associated with gliomas through naringenin-loaded nanoformulations. Here, we discuss several nanocarriers employed as delivery systems, including polymeric nanoparticles, micelles, liposomes, solid lipid nanoparticles (SLNs), nanosuspensions, and nanoemulsions. These naringenin-loaded nanoformulations have been tested in various in vitro and in vivo models and administration routes as a potential treatment for brain disorders. The conclusion from this review is that proper nanoformulations of NRG are a possible therapeutic alternative for the treatment of neurological diseases.PMID:38347794 | DOI:10.2174/0113892010281459240118091137
Source: Current Pharmaceutical Biotechnology - Category: Biotechnology Authors: Source Type: research